ATR 1086
PLN (Phospholamban) Cardiomyopathy
Pre-clinicalLead development candidate
Key Facts
Indication
PLN (Phospholamban) Cardiomyopathy
Phase
Pre-clinical
Status
Lead development candidate
Company
About Atrium Therapeutics
Atrium Therapeutics is a private biotech company focused on transforming the standard of care for cardiac diseases by addressing their underlying genetic causes. The company launched with approximately $270 million in funding and leverages a proprietary RNA delivery platform, derived from Avidity Biosciences' AOC technology, to enable targeted oligonucleotide therapy for the heart. Its initial pipeline targets rare, life-threatening cardiomyopathies with high unmet need, positioning it as a leader in the emerging field of precision cardiology.
View full company profile